Discuss SNAP-8 on glp1chat
Join the forum to discuss research with other members.
At a glance
SNAP-8 is a cosmetic peptide studied in topical products for its possible effect on signals involved in small facial-muscle movements. Researchers assess whether a finished cream or patch changes the appearance of fine lines; the entire formula matters.
The proposed cosmetic idea is to dampen some of the signals that tell tiny facial muscles to move, which could soften the look of expression lines. For a cream or patch, the first question is whether enough intact peptide crosses the skin to reach its target. Studies usually test a complete formula, often with other ingredients. A result for that formula cannot be credited to SNAP-8 alone without a suitable comparison.
Potential benefits & side effects
Interpret each outcome in the context of the study population, formulation and evidence type. Research findings do not establish a personal treatment outcome.
Potential benefits & research findings
Developer panels, multi-active patches and conventional creams are different evidence settings. A percentage of supplier solution is not the same as the percentage of active peptide.[1][2][3]
Read the original publications to see the measured endpoints, comparator, duration and uncertainty. Mechanistic plausibility and a favorable experimental result are different from demonstrated clinical benefit.
Side effects & evidence limitations
Interpret the reported adverse effects together with the study population, route and observation period. Small or short studies can miss uncommon and delayed harms. Evidence from a related compound does not establish the safety of SNAP-8.
Source-reported adverse effects and cautions
Sources are available for independent reading. Individual claims and research schedules have not yet undergone an independent clinical review by Pep Science.
- Editorial responsibility
- Pep Science editorial desk
- Last independent review
- Not yet recorded
SPECIFICATIONS & SOURCE SCHEDULES
Explore a vial size
Select the exact formulation. Vial content, target dose and prepared concentration are different measurements.
Showing 10 mg · 5 source tables
Whole 10 mg Vial Concentration Calculator
| Final Batch | Active Peptide | Active % w/w | ppm | Research Context |
|---|---|---|---|---|
| 30 g | 10 mg | 0.0333% w/w | 333 ppm | About 6.7 times the upper developer reference |
| 50 g | 10 mg | 0.0200% w/w | 200 ppm | 4 times the upper developer reference |
| 100 g | 10 mg | 0.0100% w/w | 100 ppm | 2 times the upper developer reference |
| 200 g | 10 mg | 0.0050% w/w | 50 ppm | Matches 10% of the nominal 0.05% supplier solution |
| 333.3 g | 10 mg | 0.0030% w/w | 30 ppm | Mid-range calculation |
| 666.7 g | 10 mg | 0.0015% w/w | 15 ppm | Matches 3% of the nominal 0.05% supplier solution |
These rows show the mathematical concentration produced when the complete 10 mg vial is distributed through a measured final batch weight. The 200 g to 666.7 g rows span the developer’s finished-active reference range. Smaller batches produce higher concentrations. Formula: Active percent w/w = peptide mg divided by final batch grams divided by 10. Parts per million = peptide mg divided by final batch grams multiplied by 1,000.
Small-Batch SNAP-8 Research Calculations
| Final Batch | 0.0015% Active | 0.0030% Active | 0.0050% Active |
|---|---|---|---|
| 30 g | 0.45 mg | 0.90 mg | 1.50 mg |
| 50 g | 0.75 mg | 1.50 mg | 2.50 mg |
| 100 g | 1.50 mg | 3.00 mg | 5.00 mg |
| 200 g | 3.00 mg | 6.00 mg | 10.00 mg |
A typical 30 g or 50 g topical batch requires a measured portion of the vial to match the 0.0015% to 0.005% active reference range. Formula: Peptide mg needed = target percent multiplied by final batch grams multiplied by 10.
Worked 1 mg/mL Stock Measurement Example
| Final Batch | Stock for 0.0015% | Stock for 0.0030% | Stock for 0.0050% |
|---|---|---|---|
| 30 g | 0.45 mL | 0.90 mL | 1.50 mL |
| 50 g | 0.75 mL | 1.50 mL | 2.50 mL |
| 100 g | 1.50 mL | 3.00 mL | 5.00 mL |
If a validated formulation plan uses the complete 10 mg vial in a measured 10.0 mL final stock volume, the nominal stock concentration is 1 mg/mL. Each 1.0 mL contains 1.0 mg SNAP-8. The stock must use a compatible vehicle, and the transferred amount becomes part of the final batch. Important: This is measurement math, not a shelf-life claim. A base must accept the added aqueous phase without losing homogeneity or preservation. An analytical standard remained stable for 96 hours at 4 degrees C, but this does not validate a multiweek topical stock or cream[5].
How to Read the 3% to 10% SNAP-8 Range
| Trade Solution | Peptide in Stock | Final Active % | Equivalent ppm |
|---|---|---|---|
| 3% | 0.05% | 0.0015% | 15 ppm |
| 6% | 0.05% | 0.0030% | 30 ppm |
| 10% | 0.05% | 0.0050% | 50 ppm |
The ingredient developer supplied SNAP-8 as a preserved aqueous blend containing approximately 0.05% acetyl octapeptide-3. Adding 3% to 10% of that solution gives 0.0015% to 0.005% actual peptide in the final product[6]. A raw 10 mg vial and a preserved commercial premix are not operationally interchangeable. Concentration math does not validate homogeneity, preservation, pH, compatibility, skin delivery, or shelf life. Those controls belong to the finished formulation.
Human SNAP-8 Research Formulations
| Study | Formulation | Schedule | Design Context | Evidence Limit |
|---|---|---|---|---|
| Lipotec developer panel[6] | Cream with 10% of a nominal 0.05% SNAP-8 solution, equal to about 0.005% active peptide | Twice daily around the eye area for 28 days | 17 women; silicone replicas and profilometry; about 35% mean and 63% maximum wrinkle-depth reduction reported | Manufacturer-reported, not an independent peer-reviewed trial |
| Shin et al. (2024)[1] | 350 micrometer dissolving patch with 0.03% SNAP-8, 5% AA2G, 4% cyclic LPA, and 90% HA | Overnight nightly through day 14, then every third day through day 28 | 24 enrolled and 21 completed a split-face active-versus-placebo comparison | Combination device; SNAP-8’s independent contribution cannot be isolated |
| Avcil et al. (2020)[2] | HA microneedle patch with SNAP-8, other peptides, adenosine, and seaweed extracts | 12-week study | Fine lines, hydration, dermal density, thickness, and tolerability measures | Multi-active product; SNAP-8 concentration was not disclosed in the abstract |
| Draelos et al. (2016)[3] | Multi-peptide serum containing SNAP-8 within a supporting skincare regimen | Morning and evening for 12 weeks after a 2-week washout | 29 women; investigator grading and participant questionnaires | Open label, no control, multiple peptides and supporting products |
| Moy et al. (2023)[4] | Proprietary multi-peptide facial serum containing acetyl octapeptide-3 | Twice daily for 12 weeks | 31 women completed dermatologist grading, imaging, hydration, and questionnaires | Uncontrolled, multi-ingredient, and company funded |
Human evidence is topical or device-assisted. Conventional cream data come from ingredient-developer testing. Peer-reviewed studies used multi-active serums or dissolving microneedle patches, so their outcomes cannot be assigned to SNAP-8 alone.
Additional schedule context & duration
- Developer active reference: Approximately 0.0015% to 0.005% active SNAP-8.
- Best documented conventional cream example: Approximately 0.005% active peptide.
- Application context: Twice daily around the eye area for 28 days in manufacturer testing.
- Academic serum context: Morning and evening or twice-daily use for 12 weeks in multi-ingredient studies.
- Patch context: Overnight nightly through day 14, then every third day through day 28 in a manufactured multi-active patch.
- 10 mg in 200 g: 0.005% w/w or 50 ppm.
- 10 mg in 333.3 g: 0.003% w/w or 30 ppm.
- 10 mg in 666.7 g: 0.0015% w/w or 15 ppm.
- 50 g batch at 0.005%: 2.5 mg active peptide.
Read this protocol on Pep Science → · View cited documents ↓
Preparation
Storage and Stability Controls
- Follow the vial supplier’s lot-specific storage documentation before formulation.
- Store the finished batch according to its validated base, preservative, pH, container, and stability plan.
- Do not transfer the trade solution’s published shelf life to a raw-vial formulation.
- An analytical standard remained stable for 96 hours at 4 degrees C, but that does not establish cosmetic-product shelf life[5].
Topical Preparation Planning
- Confirm active mass: Adjust the nominal 10 mg amount if the lot assay requires it.
- Select the research concentration: Keep the percentage attached to its source, vehicle, route, and schedule.
- Calculate peptide mass: Use the small-batch table for the selected final weight.
- Define the stock method: If the mass is below the balance’s reliable range, use an accurately quantified stock in a compatible vehicle under a validated plan.
- Transfer and mix: Include the complete measured stock in the final batch and use a validated method for uniform dispersion.
- Verify the batch: Record final weight, pH, appearance, packaging, dispensing amount, preservation controls, and testing.
- Label the study unit: Include concentration, batch ID, date, storage, and observation schedule.
Topical Application and Measurement Controls
- Measure the dispensed amount: Use a calibrated pump, positive-displacement tool, or before-and-after container weight.
- Keep the target area consistent: Apply to the predefined external skin area and prevent direct eye or mucosal contact.
- Control the vehicle: Record the base formula because it affects spread, stability, preservation, and delivery.
- Do not equate delivery systems: A 0.03% dissolving microneedle patch is not equivalent to a 0.03% intact-skin cream[1][5].
Materials & quantity planning
Source materials checklist · 10 mg
Use a complete, measured formulation set for each SNAP-8 topical research batch.
- SNAP-8 10 mg research vial: Record lot number, identity, assay, purity, and certificate of analysis.
- Validated cosmetic research base: A compatible cream, gel, or serum base with a documented formula and preservation system.
- Compatible stock vehicle: Use only when a validated formulation plan requires a measured stock.
- Calibrated analytical balance: Needed for final batch weight and direct mass measurements within its validated range.
- Calibrated pipettes or positive-displacement tools: Needed when an accurately quantified liquid stock is used.
- Clean mixing and transfer tools: A suitable vessel, spatula, transfer tools, and validated homogenization method.
- pH measurement: A calibrated meter or validated narrow-range strips.
- Clean handling supplies: Clean gloves, alcohol preparation materials, and a disinfected work surface.
- Final container: A compatible opaque or airless container with a secure closure and measurable dispenser.
- Label and batch log: Record active mass, final weight, concentration, vehicle, pH, container, date, storage, and observations.
- Stability observation log: Track appearance, odor, separation, pH drift, container compatibility, and validated testing.
Quantity estimates exclude preparation losses and expiry. Follow the formulation’s handling and disposal requirements.
FOLLOW THE EVIDENCE
References & further reading
Original publications and source documents cited across this product’s variants. A listed source is not an independent endorsement of a dosing schedule.